Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Non-Current Assets (2023 - 2025)

Ascentage Pharma Group International posted quarterly Non-Current Assets of $143.7 million for Q4 2025, down 9.73% year-on-year from $159.2 million in Q4 2024, and down 9.48% on a QoQ basis from $158.8 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Non-Current Assets data on file, last reported at $143.7 million in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 9.73% year-over-year to $143.7 million; the trailing twelve-month figure through Dec 2025 stood at $143.7 million (down 9.73% YoY), and the FY2025 full-year result was $145.8 million, down 6.96% from the prior year.
  • Non-Current Assets for Q4 2025 stood at $143.7 million, down from $158.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $160.6 million in Q4 2023 and bottomed at $143.7 million in Q4 2025.
  • The 3-year median for Non-Current Assets is $159.0 million (2024), against an average of $155.6 million.
  • The widest annual swing landed in 2024, when Non-Current Assets retreated 0.85%; it then dropped 9.73% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $160.6 million in 2023, then dropped by 0.85% to $159.2 million in 2024, then dropped by 9.73% to $143.7 million in 2025.
  • The last three Non-Current Assets figures came in at $143.7 million (Q4 2025), $158.8 million (Q2 2025), and $159.2 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - 4.56 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 62,953.78
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 486.60 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - 5.83 Mn
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 14.75 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 22.66 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 910.24 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 143.73 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 143.73 Mn
Jun 30, 2025 158.78 Mn
Dec 31, 2024 159.21 Mn
Dec 31, 2023 160.58 Mn